drugset / Trial / NCT00422461
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
Timeline
- Start
- 2007-02-27
- Primary completion
- 2008-01-28
- Completion
- 2008-01-28
Outcome
Met primary endpoint
registry analysis (superiority test); Placebo vs PF-00489791 10 mg; p = 0.0170; LS mean difference -4.66 (95% CI -8.47 to -0.85); Nonlinear dose response regression model NCT00422461 ↗
registry analysis (superiority test); Placebo vs PF-00489791 20/40 mg; p = 0.0026; LS mean difference -6.97 (95% CI -11.45 to -2.48); Nonlinear dose response regression model NCT00422461 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-00489791 | Small molecule | 4 mg | Oral |
| Subject | PF-00489791 | Small molecule | 10 mg | Oral |
| Subject | PF-00489791 | Small molecule | 40 mg | Oral |